45 results about "Head neck cancer" patented technology

The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and / or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

The present invention provides antibodies that can be used as therapeutic agents for the treatment and / or prevention of diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, Liver, head and neck and gallbladder cancers.

The present invention relates to HPV-positive as well as HPV-negative screening platforms that are highly serum-dependent, for use as HNSCC models. These HNSCC models die reproducibly in serum-deprived conditions and the introduction of driver mutations (or increased levels of the WT gene) confers enhanced cell survival and proliferation under serum deprivation. These platforms have the major advantages of allowing functional screening of mutations in relevant HNSCC models (HPV-positive and HPV-negative). In addition to oncogene screening, this model can also be used in drug discovery. Specifically, cells expressing mutations that confer increased survival can then be screened against panels of therapeutic agents to determine if the mutation(s) can predict the optimal treatment for patients whose tumors harbor the mutation(s).

The invention discloses a novel molecular marker and its application in preparation of a kit for the diagnosis and prognosis of head and neck cancer. The RNA sequences of the novel molecular marker are shown in SEQ ID NO:1-SEQ ID NO:48. Based on the marker of the invention, a mathematical model for the diagnosis of head and neck cancer is constructed; the model has high sensitivity, good specificity, AUC up to 0.981, and good diagnostic effect. In addition, these 48 tRF fragments can also be used as molecular markers for head and neck cancer classification and prediction of patient survival; in the test data, according to the expression of tRFs, head and neck cancer tumor samples were clustered into 4 subtypes, and analyzed by survival curves It shows that there are significant differences in the survival periods of these subtypes; the novel tRF molecular marker disclosed in the present invention has the characteristics of good diagnostic indicators, can be effectively used in the diagnosis, classification and prognosis of head and neck cancer, and has high clinical application and promotion value.